Conclusions
RS, MP
ONCOLOGY, REGRESSION, DISEASE
Taken together, our trial data demonstrate the feasibility of daily app-based treatment surveillance in patients with HNC undergoing radiotherapy. ePRO monitoring in this setting improved reporting of disease- and treatment-related symptom burden and significantly increased patient satisfaction. Further analyses are needed to assess whether our findings hold true outside the context of a clinical trial and if feasibility results are transferrable to other disease sites.This trial was supported by the State of Baden-Württemberg through the “Centers for Innovative Health Services” initiative. The app used for this trial was provided by ONCARE GmbH through a research cooperation agreement with the University of Freiburg. The authors would like to thank the clinical trials staff at the Department of Radiation Oncology, University of Freiburg Medical Center, for their support of this trial.Authors' Contributions: TS and NHN developed this trial. NHN wrote the manuscript. MP, DZ, and HB were responsible for the statistical aspects of this trial. RS, EC, AR, AF, EG, and ALG helped with the trial design and recruited patients. HF and FH provided and maintained the required information technology infrastructure necessary for this trial and managed the electronic data. All authors read and approved the final manuscript.Conflicts of Interest: None declared.Logistic regression model for the covariates.CONSORT checklist.